Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 192.88
ABAX's Cash to Debt is ranked higher than
79% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.24 vs. ABAX: 192.88 )
ABAX' s 10-Year Cash to Debt Range
Min: 0.46   Max: No Debt
Current: 192.88

Equity to Asset 0.87
ABAX's Equity to Asset is ranked higher than
91% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. ABAX: 0.87 )
ABAX' s 10-Year Equity to Asset Range
Min: 0.48   Max: 0.9
Current: 0.87

0.48
0.9
F-Score: 4
Z-Score: 25.38
M-Score: -2.88
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 14.56
ABAX's Operating margin (%) is ranked higher than
91% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.89 vs. ABAX: 14.56 )
ABAX' s 10-Year Operating margin (%) Range
Min: -930   Max: 22.65
Current: 14.56

-930
22.65
Net-margin (%) 9.27
ABAX's Net-margin (%) is ranked higher than
87% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.31 vs. ABAX: 9.27 )
ABAX' s 10-Year Net-margin (%) Range
Min: -900   Max: 51.27
Current: 9.27

-900
51.27
ROE (%) 8.85
ABAX's ROE (%) is ranked higher than
77% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.65 vs. ABAX: 8.85 )
ABAX' s 10-Year ROE (%) Range
Min: -61.71   Max: 62.55
Current: 8.85

-61.71
62.55
ROA (%) 7.77
ABAX's ROA (%) is ranked higher than
87% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.89 vs. ABAX: 7.77 )
ABAX' s 10-Year ROA (%) Range
Min: -49.56   Max: 50.99
Current: 7.77

-49.56
50.99
ROC (Joel Greenblatt) (%) 35.45
ABAX's ROC (Joel Greenblatt) (%) is ranked higher than
86% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.61 vs. ABAX: 35.45 )
ABAX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -154.55   Max: 57.43
Current: 35.45

-154.55
57.43
Revenue Growth (%) 6.60
ABAX's Revenue Growth (%) is ranked higher than
72% of the 152 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.60 vs. ABAX: 6.60 )
ABAX' s 10-Year Revenue Growth (%) Range
Min: 6.6   Max: 93.9
Current: 6.6

6.6
93.9
EBITDA Growth (%) 1.90
ABAX's EBITDA Growth (%) is ranked higher than
73% of the 125 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.50 vs. ABAX: 1.90 )
ABAX' s 10-Year EBITDA Growth (%) Range
Min: -33.7   Max: 171.4
Current: 1.9

-33.7
171.4
EPS Growth (%) -0.50
ABAX's EPS Growth (%) is ranked higher than
70% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.60 vs. ABAX: -0.50 )
ABAX' s 10-Year EPS Growth (%) Range
Min: -59.2   Max: 159.6
Current: -0.5

-59.2
159.6
» ABAX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

ABAX Guru Trades in Q3 2013

Jim Simons 37,971 sh (New)
RS Investment Management Sold Out
Steven Cohen Sold Out
Chuck Royce 300 sh (-99.91%)
» More
Q4 2013

ABAX Guru Trades in Q4 2013

Joel Greenblatt 25,721 sh (New)
PRIMECAP Management 575,000 sh (New)
Jim Simons 100,869 sh (+165.65%)
Chuck Royce Sold Out
» More
Q1 2014

ABAX Guru Trades in Q1 2014

PRIMECAP Management 1,979,300 sh (+244.23%)
Jim Simons Sold Out
Joel Greenblatt 20,229 sh (-21.35%)
» More
Q2 2014

ABAX Guru Trades in Q2 2014

Joel Greenblatt 26,303 sh (+30.03%)
PRIMECAP Management 1,975,700 sh (-0.18%)
» More
» Details

Insider Trades

Latest Guru Trades with ABAX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-06-30 Add 30.03%$37.95 - $44.61 $ 51.5324%26303
PRIMECAP Management 2014-03-31 Add 244.23%0.06%$36.29 - $45.01 $ 51.5330%1979300
Joel Greenblatt 2014-03-31 Reduce -21.35%0.01%$36.29 - $45.01 $ 51.5330%20229
PRIMECAP Management 2013-12-31 New Buy0.03%$32.4 - $41.25 $ 51.5340%575000
Joel Greenblatt 2013-12-31 New Buy0.02%$32.4 - $41.25 $ 51.5340%25721
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 72.00
ABAX's P/E(ttm) is ranked higher than
75% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ABAX: 72.00 )
ABAX' s 10-Year P/E(ttm) Range
Min: 10.19   Max: 122.16
Current: 72

10.19
122.16
P/B 5.70
ABAX's P/B is ranked higher than
62% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.00 vs. ABAX: 5.70 )
ABAX' s 10-Year P/B Range
Min: 2.19   Max: 13.11
Current: 5.7

2.19
13.11
P/S 6.50
ABAX's P/S is ranked higher than
62% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.96 vs. ABAX: 6.50 )
ABAX' s 10-Year P/S Range
Min: 2.48   Max: 9.5
Current: 6.5

2.48
9.5
PFCF 41.30
ABAX's PFCF is ranked higher than
85% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ABAX: 41.30 )
ABAX' s 10-Year PFCF Range
Min: 21.92   Max: 101.52
Current: 41.3

21.92
101.52
EV-to-EBIT 43.44
ABAX's EV-to-EBIT is ranked higher than
76% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ABAX: 43.44 )
ABAX' s 10-Year EV-to-EBIT Range
Min: 10.6   Max: 111.5
Current: 43.44

10.6
111.5
PEG 8.76
ABAX's PEG is ranked higher than
86% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ABAX: 8.76 )
ABAX' s 10-Year PEG Range
Min: 0.7   Max: 13.47
Current: 8.76

0.7
13.47
Shiller P/E 66.60
ABAX's Shiller P/E is ranked higher than
85% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ABAX: 66.60 )
ABAX' s 10-Year Shiller P/E Range
Min: 21.13   Max: 317.57
Current: 66.6

21.13
317.57
Current Ratio 7.46
ABAX's Current Ratio is ranked higher than
90% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.56 vs. ABAX: 7.46 )
ABAX' s 10-Year Current Ratio Range
Min: 1.54   Max: 9.82
Current: 7.46

1.54
9.82
Quick Ratio 6.29
ABAX's Quick Ratio is ranked higher than
90% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.29 vs. ABAX: 6.29 )
ABAX' s 10-Year Quick Ratio Range
Min: 1.12   Max: 8.45
Current: 6.29

1.12
8.45

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.40
ABAX's Dividend Yield is ranked lower than
90% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.28 vs. ABAX: 0.40 )
ABAX' s 10-Year Dividend Yield Range
Min: 0.19   Max: 0.23
Current: 0.4

0.19
0.23
Dividend Payout 0.14
ABAX's Dividend Payout is ranked higher than
96% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ABAX: 0.14 )
ABAX' s 10-Year Dividend Payout Range
Min: 0.48   Max: 0.48
Current: 0.14

Yield on cost (5-Year) 0.40
ABAX's Yield on cost (5-Year) is ranked lower than
90% of the 62 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. ABAX: 0.40 )
ABAX' s 10-Year Yield on cost (5-Year) Range
Min: 0.19   Max: 0.23
Current: 0.4

0.19
0.23
Share Buyback Rate 0.40
ABAX's Share Buyback Rate is ranked higher than
90% of the 145 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.70 vs. ABAX: 0.40 )
ABAX' s 10-Year Share Buyback Rate Range
Min: 0.4   Max: -18
Current: 0.4

Valuation & Return

vs
industry
vs
history
Price/Net Cash 14.90
ABAX's Price/Net Cash is ranked higher than
86% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ABAX: 14.90 )
ABAX' s 10-Year Price/Net Cash Range
Min: 5.92   Max: 300
Current: 14.9

5.92
300
Price/Net Current Asset Value 9.90
ABAX's Price/Net Current Asset Value is ranked higher than
86% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ABAX: 9.90 )
ABAX' s 10-Year Price/Net Current Asset Value Range
Min: 4.17   Max: 287.5
Current: 9.9

4.17
287.5
Price/Tangible Book 5.90
ABAX's Price/Tangible Book is ranked higher than
70% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.92 vs. ABAX: 5.90 )
ABAX' s 10-Year Price/Tangible Book Range
Min: 2.17   Max: 36.9
Current: 5.9

2.17
36.9
Price/DCF (Projected) 2.90
ABAX's Price/DCF (Projected) is ranked higher than
81% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ABAX: 2.90 )
ABAX' s 10-Year Price/DCF (Projected) Range
Min: 1.7   Max: 180.9
Current: 2.9

1.7
180.9
Price/Median PS Value 1.30
ABAX's Price/Median PS Value is ranked higher than
69% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.26 vs. ABAX: 1.30 )
ABAX' s 10-Year Price/Median PS Value Range
Min: 0.31   Max: 8.88
Current: 1.3

0.31
8.88
Price/Peter Lynch Fair Value 7.30
ABAX's Price/Peter Lynch Fair Value is ranked higher than
87% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ABAX: 7.30 )
ABAX' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.52   Max: 11.31
Current: 7.3

0.52
11.31
Price/Graham Number 4.40
ABAX's Price/Graham Number is ranked higher than
80% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ABAX: 4.40 )
ABAX' s 10-Year Price/Graham Number Range
Min: 1.42   Max: 10.96
Current: 4.4

1.42
10.96
Earnings Yield (Greenblatt) 2.30
ABAX's Earnings Yield (Greenblatt) is ranked higher than
73% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.70 vs. ABAX: 2.30 )
ABAX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.9   Max: 9.5
Current: 2.3

0.9
9.5
Forward Rate of Return (Yacktman) 11.26
ABAX's Forward Rate of Return (Yacktman) is ranked higher than
84% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.68 vs. ABAX: 11.26 )
ABAX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -1.1   Max: 43.2
Current: 11.26

-1.1
43.2

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:AXS.Germany
Abaxis, Inc. was incorporated in California in 1989. The Company develops, manufactures, markets and sells portable blood analysis systems for use in the human or veterinary patient-care setting to provide clinicians with rapid blood constituent measurements. It offers point-of-care blood chemistry analyzer, which consists of a compact portable analyzer and a series of single-use plastic discs, called reagent discs, containing all the chemicals required to perform a panel of up to 14 tests on human patients and 13 tests on veterinary patients. The Company markets the blood analysis systems under the Piccolo Xpress, Piccolo Classic, VetScan VS2, and VetScan Classic names. The Company also provides VetScan HM5, VetScan HM2, VetScan HMII, and VetScan HMT hematology instruments, as well as reagent kits for veterinary applications. In addition, it offers VetScan VSpro, which assists in the diagnosis and evaluation of suspected bleeding disorders, toxicity/poisoning, evaluation of disseminated intravascular coagulation, hepatic disease, monitoring therapy, and the progression of disease states; VetScan VSpro fibrinogen test to provide in-vitro determination of fibrinogen levels in equine platelet poor plasma from a citrated stabilized whole blood sample; and i-STAT 1 that delivers blood gas, electrolyte, basic blood chemistry, and hematology results. Further, the company provides Canin Heartworm rapid test to detect dirofilaria immitis in canine whole blood, serum, or plasma; Canine Parvovirus rapid test to detect canine parvovirus antigen in feces; VetScan Giardia rapid test to detect giardiasis, a gastrointestinal infection caused by the protozoan parasite Giardia; and Canine Lyme rapid test to detect Borrelia burgdorferi in canine whole blood, serum, or plasma. Additionally, it offers veterinary reference laboratory diagnostic and consulting services. The Company sells its products through direct sales force and independent distributors.
» More Articles for ABAX

Headlines

Articles On GuruFocus.com
ABAXIS Inc. (ABAX) COO Donald Peter Wood sells 6,460 Shares Mar 08 2011 
ABAXIS Inc. (ABAX) President,CEO & Board Chairman Clinton Severson sells 35,000 Shares Dec 10 2010 
ABAXIS Inc. (ABAX) President,CEO & Board Chairman Clinton Severson sells 96,000 Shares Dec 08 2010 
ABAXIS Inc. (ABAX) President,CEO & Board Chairman Clinton Severson sells 66,029 Shares Dec 07 2010 
ABAXIS Announces Contract Manufacturing Agreement with SA Scientific, Ltd. Jan 13 2009 


More From Other Websites
Medical Equipment Stocks Rise; Idexx Clears Buy Point Oct 28 2014
ABAXIS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a... Oct 28 2014
Abaxis Declares Quarterly Cash Dividend Oct 23 2014
Abaxis Announces Appointment of Ross Taylor as Vice President of Business Development & Investor... Oct 23 2014
Abaxis Announces Appointment of Ross Taylor as Vice President of Business Development & Investor... Oct 23 2014
ABAXIS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Oct 23 2014
Abaxis Declares Quarterly Cash Dividend Oct 23 2014
Trade-Ideas: Abaxis (ABAX) Is Today's Strong And Under The Radar Stock Oct 22 2014
Abaxis Tops Q3 Earnings and Revenues, Margins Up Y/Y Oct 22 2014
Abaxis tops Street 2Q forecasts Oct 21 2014
Abaxis tops Street 2Q forecasts Oct 21 2014
Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 Oct 21 2014
ABAXIS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Oct 21 2014
Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 Oct 21 2014
Henry Schein Animal Health Announces Strategic Relationship With Abaxis To Bring Diagnostic Products... Oct 21 2014
Abaxis Announces Distribution Agreement with Henry Schein Animal Health Oct 21 2014
Q2 2015 Abaxis Inc Earnings Release - After Market Close Oct 21 2014
Abaxis Announces Distribution Agreement with Henry Schein Animal Health Oct 21 2014
Henry Schein Animal Health Announces Strategic Relationship With Abaxis To Bring Diagnostic Products... Oct 21 2014
Why Abaxis (ABAX) Might Surprise This Earnings Season Oct 17 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK